Atrial Fibrillation (AF) Ablation to Prevent Disease Progression of AF-induced Atrial Cardiomyopathy in Women and Men

Inclusion criteria - Confirmed ACMP (LAVI \>34 ml/m2) - ECG-confirmed AF - Age: 65-80 years old - Patients eligible for both treatment strategies judged by the treating physician signed and dated willing to sign a consent form prior to admission to the trial Exclusion criteria - Longstanding (\>1 year) persistent or permanent (accepted) AF - Previous left atrial (LA) ablation or LA surgery - AF due to a reversible cause (e.g. hyperthyroidism, post-operative AF) - Recent (\<90 days) acute coronary syndrome, stroke/TIA or cardiac intervention (Cardiac interventions include percutaneous coronary intervention, coronary artery bypass grafting, and heart valve repair or replacement (endovascular or surgical)) - Intracardiac thrombus - HF NYHA III/IV - Impaired renal function, defined as estimated glomerular filtration rate ≤25 ml/min/1.73m2 - Presence of (or scheduled for) mechanical assist device or heart transplant - Severe aortic or mitral valve disease - Complex congenital heart disease - Life expectancy \<1 year - Currently enrolled in another clinical randomized trial Always talk to your doctor about whether this trial is right for you.